Milestone Pharmaceuticals INC 10-Q quarterly reports

Milestone Pharmaceuticals Inc. reports on the commercial launch of CARDAMYST, progress in its AFib-RVR clinical program, and financial updates for the quarter ended June 30, 2026.

Milestone Pharmaceuticals Inc. reported its first quarter 2026 financial results, marking the initial product revenue from CARDAMYST and detailing ongoing clinical development for AFib-RVR.

Milestone Pharmaceuticals reports increased net losses in Q3 2025, driven by commercialization preparations, while advancing etripamil's FDA approval pathway and clinical development for cardiovascular indications.

Milestone Pharmaceuticals reports increased losses but strengthens liquidity with a new $48.7 million public offering and an extended royalty agreement, as its lead drug etripamil nears FDA approval with a December 13, 2025 PDUFA date.

Milestone Pharmaceuticals received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT), citing CMC issues.

Milestone Pharmaceuticals reported its Q3 2024 financial results and provided updates on the regulatory progress of its lead product candidate, etripamil.

Milestone Pharmaceuticals reported a net loss of $9.4 million for the second quarter of 2024, alongside updates on their lead product candidate, etripamil.

Milestone Pharmaceuticals resubmitted its New Drug Application for etripamil to the FDA and reported a net loss of $10.4 million for the first quarter of 2024.